Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial.

Cancer Immunol Immunother · 2026 · PMC12847568 · PMID 41591582

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significanceP = 0.13not close (p > 0.1)

OS also favored the immunotherapy group, although the difference did not reach statistical significance (HR = 0.70, 95% CI 0.44–1.11, P = 0.13; Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.